-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Benzinga·02/09/2026 19:30:35
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.